BackCytoMed Therapeutics Overview

CytoMed Therapeutics Profit Margin

Latest profit margin for CytoMed Therapeutics: -1065.07% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-1030.69%
↑ 49.85% YoY

As of Dec 2025

Annual Profit Margin (TTM)

-1065.07%

Trailing 12 months ending Dec 2025

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading
Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

CytoMed Therapeutics (GDTC) FAQ

The latest profit margin for GDTC is -1065.07% as of December 2025. That is below the sector sector average of 19.61%. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, GDTC currently prints -1065.07% for profit margin, while the sector average sits near 19.61%. That is roughly 5532.2% below the sector mean. Large gaps often invite a closer look at CytoMed Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively CytoMed Therapeutics converts resources into returns. At -1065.07%, GDTC may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GDTC's profit margin (-1065.07%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.